Biomarkers in Parkinson's disease

John Christopher Morgan, Shyamal H. Mehta, Kapil Dev Sethi

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes, or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson's disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential biomarkers are inexpensive and do not require much technical expertise, whereas others are expensive or require specialized equipment and technical skills. Many potential biomarkers in PD show great promise; however, they need to be assessed for their sensitivity and specificity over time in large and varied samples of patients with and without PD.

Original languageEnglish (US)
Pages (from-to)423-430
Number of pages8
JournalCurrent Neurology and Neuroscience Reports
Volume10
Issue number6
DOIs
StatePublished - Nov 1 2010

Fingerprint

Parkinson Disease
Biomarkers
Disease Progression
Professional Competence
Biological Phenomena
Metabolomics
Neuroimaging
Proteomics
Cerebrospinal Fluid
Differential Diagnosis
Research Personnel
Sensitivity and Specificity
Equipment and Supplies
Therapeutics

Keywords

  • 8-hydroxydeoxyguanosine (8-OHdG)
  • Biomarkers
  • Diffusion tensor imaging (DTI)
  • Dopamine transporter
  • Gene expression profiling
  • Glucocerebrosidase
  • Hoehn and Yahr staging
  • Leucine-rich repeat kinase-2 (LRRK2)
  • Metabolomics
  • Metaiodobenzylguanidine (MIBG)
  • Non-Motor Questionnaire and Scale
  • Parkin
  • Parkinson's disease
  • Proteomics
  • REM behavior disorder
  • Radiotracer neuroimaging
  • Transcranial ultrasound
  • Unified Parkinson's Disease Rating Scale (UPDRS)
  • University of Pennsylvania Smell Identification Test (UPSIT)
  • Uric acid
  • α-Synuclein

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Biomarkers in Parkinson's disease. / Morgan, John Christopher; Mehta, Shyamal H.; Sethi, Kapil Dev.

In: Current Neurology and Neuroscience Reports, Vol. 10, No. 6, 01.11.2010, p. 423-430.

Research output: Contribution to journalReview article

Morgan, John Christopher ; Mehta, Shyamal H. ; Sethi, Kapil Dev. / Biomarkers in Parkinson's disease. In: Current Neurology and Neuroscience Reports. 2010 ; Vol. 10, No. 6. pp. 423-430.
@article{93b7bb48ab644bd0840bd298ca67bf9d,
title = "Biomarkers in Parkinson's disease",
abstract = "Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes, or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson's disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential biomarkers are inexpensive and do not require much technical expertise, whereas others are expensive or require specialized equipment and technical skills. Many potential biomarkers in PD show great promise; however, they need to be assessed for their sensitivity and specificity over time in large and varied samples of patients with and without PD.",
keywords = "8-hydroxydeoxyguanosine (8-OHdG), Biomarkers, Diffusion tensor imaging (DTI), Dopamine transporter, Gene expression profiling, Glucocerebrosidase, Hoehn and Yahr staging, Leucine-rich repeat kinase-2 (LRRK2), Metabolomics, Metaiodobenzylguanidine (MIBG), Non-Motor Questionnaire and Scale, Parkin, Parkinson's disease, Proteomics, REM behavior disorder, Radiotracer neuroimaging, Transcranial ultrasound, Unified Parkinson's Disease Rating Scale (UPDRS), University of Pennsylvania Smell Identification Test (UPSIT), Uric acid, α-Synuclein",
author = "Morgan, {John Christopher} and Mehta, {Shyamal H.} and Sethi, {Kapil Dev}",
year = "2010",
month = "11",
day = "1",
doi = "10.1007/s11910-010-0144-0",
language = "English (US)",
volume = "10",
pages = "423--430",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Biomarkers in Parkinson's disease

AU - Morgan, John Christopher

AU - Mehta, Shyamal H.

AU - Sethi, Kapil Dev

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes, or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson's disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential biomarkers are inexpensive and do not require much technical expertise, whereas others are expensive or require specialized equipment and technical skills. Many potential biomarkers in PD show great promise; however, they need to be assessed for their sensitivity and specificity over time in large and varied samples of patients with and without PD.

AB - Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes, or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson's disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential biomarkers are inexpensive and do not require much technical expertise, whereas others are expensive or require specialized equipment and technical skills. Many potential biomarkers in PD show great promise; however, they need to be assessed for their sensitivity and specificity over time in large and varied samples of patients with and without PD.

KW - 8-hydroxydeoxyguanosine (8-OHdG)

KW - Biomarkers

KW - Diffusion tensor imaging (DTI)

KW - Dopamine transporter

KW - Gene expression profiling

KW - Glucocerebrosidase

KW - Hoehn and Yahr staging

KW - Leucine-rich repeat kinase-2 (LRRK2)

KW - Metabolomics

KW - Metaiodobenzylguanidine (MIBG)

KW - Non-Motor Questionnaire and Scale

KW - Parkin

KW - Parkinson's disease

KW - Proteomics

KW - REM behavior disorder

KW - Radiotracer neuroimaging

KW - Transcranial ultrasound

KW - Unified Parkinson's Disease Rating Scale (UPDRS)

KW - University of Pennsylvania Smell Identification Test (UPSIT)

KW - Uric acid

KW - α-Synuclein

UR - http://www.scopus.com/inward/record.url?scp=78049293738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049293738&partnerID=8YFLogxK

U2 - 10.1007/s11910-010-0144-0

DO - 10.1007/s11910-010-0144-0

M3 - Review article

VL - 10

SP - 423

EP - 430

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 6

ER -